Immunosuppressed transplant recipients between the ages of 12 to 17-years-old have been added to the MELODY study population, which analyses how well additional doses of the COVID-19 vaccine protects immunosuppressed people.
The research project was first launched in December 2021 to evaluate third doses in adult patients and was supported by a coalition of funders including Kidney Research UK, The Medical Research Council, Blood Cancer UK, Vasculitis UK and the Cystic Fibrosis Trust…
